The clinical significance of level changes of hs-CRP, IL-10 and TNF for patients with MS during active and relieving period.
To investigate the clinical significance of the change of the level of hs-CRP, interleukin-10 (IL-10) and tumor necrosis factors (TNF-α) for patients with multiple sclerosis (MS) during the active and the relieving period.



36 patients with MS during the active stage and the relieving stage after therapy (experimental group) were compared with 10 healthy people at the relieving period, considered as control group. Immunoturbidimetry was used to examine levels of hs-CRP while the level of IL-10 and TNF-a were tested by enzyme-linked immunosorbent assay (ELISA).



Levels of hs-CRP, TNF-a and IL-10 in the serum and cerebral spinal fluid (CSF) were different for MS patient at different stages. Levels of hs-CRP, TNF-a and CSF IL-10 at attacking stage were higher than those at the relieving stage (p <0.05, p <0.01 or p <0.001). The levels of IL-10 in the serum at relieving stage were higher than in the CSF (p <0.05). The levels of TNF-a and IL-10 of MS patients at relieving stage in the serum and CFS were higher than those of healthy people (p <0.05 or p <0.01).



The significantly increased levels of hs-CRP, TNF-a and CSF IL-10 in the serum and CSF reflect MS at attack stage. The levels of TNF-a and IL-10 in the serum and CSF at the relieving stage of MS patients were higher than those of healthy individuals, suggest that at relieving stage, MS may be still developing. Finally, the increased level of hs-CRP in the serum can be used as an evidence to diagnose MS at the active stage.
Department of Neurology, The Third People Hospital of Xuzhou, Xuzhou, China. ftmlb8556215@163.com.
A-L
AL
Ji
Z-H
ZH
Liu
W-W
WW
Chen
W-J
WJ
Huang
D000293:Adolescent; D000328:Adult; D015415:Biomarkers; D002097:C-Reactive Protein; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000235:genetics*; D014409:Tumor Necrosis Factor-alpha; D055815:Young Adult
D015415:Biomarkers; C508609:IL10 protein, human; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D002097:C-Reactive Protein